HIV-1整合酶抑制剂基因突变耐药研究  

Drug-resistant gene mutations of HIV-1 integrase inhibitors

作　　者：邓雪媚 刘家法 董兴齐 Deng XM;Liu JF;Dong XQ(College of Public Hygiene, Dali University, Dali 671000, Yunnan, China;Yunnan Provincial Infectious Diseases Hospital/AIDS Care Center, Kunming 650301, Chin)

机构地区：[1]大理大学公共卫生学院,云南大理671000 [2]云南省传染病专科医院/艾滋病关爱中心,昆明650301

出　　处：《国际流行病学传染病学杂志》2018年第3期195-199,共5页International Journal of Epidemiology and Infectious Disease

基　　金：云南省科技计划（2016BC005）;云南省教育厅科学研究基金（2018JS252）

摘　　要：HIV在整合酶作用下进入人类基因组是病毒利用人类宿主细胞机制完成其自身复制和增殖的第一步，也是整个病毒感染周期的关键步骤。整合酶抑制剂以全新的作用机制在抗病毒中起到了有效作用，但也因其耐药问题的出现仍无法实现持久完全的病毒抑制。此文综述了目前主要的HIV-1整合酶抑制剂相关的耐药基因突变情况及耐药突变对整合酶效率和病毒复制适应性的影响。The entry of HIV into the human genome by integrase is the first step in the virus＇s use of human host cell machinery to achieve its own replication and proliferation, which is also a key step in the entire virus infection cycle. Integrase inhibitor （INI）, represented by rahegravir （RAL）, elvitegravir （EVG） and dolutegravir （DTG）, plays an effective role in the antiviral action with a novel mechanism of action, but still fail to complete virus suppression persistently due to the emergence of INI resistance. The mutations in the three major HIV-1 integrase inhibitors and the effects of drug-resistant mutations on the integrase efficiency and the adaptability to virus replication are summarized in this review.

关 键 词：HIV-1 整合酶抑制剂 耐药突变 酶效率 复制适应性 

分 类 号：R373[医药卫生—病原生物学]